Download original image
Fig. 1. (A) Pathways targeted by currently available senolytic and senostatic drugs. (B) Human diseases have been shown to be delayed by senotherapy (modified from ). EFNB1, ephrin B1; GF, growth factor; PI3K, phosphoinositide 3-kinases; MDM2, mouse double minute 2 homolog; Bcl2, B-cell lymphoma 2; Mcl-1, myeloid cell leukemia 1; Bcl-xL, B-cell lymphoma-extra large; FOXO4, forkhead Box O4; D + Q, co-treatment of dasatinib and quercetin.
© Mol. Cells